Generic portfolio management: A paradigm for minimizing risk and maximizing value

Abstract

Optimal product portfolio management is increasingly important for generic pharmaceutical companies in today’s intensely competitive environment. Strategic focus and front-level risk management are imperative for ensuring maximum value. This article addresses the key considerations and risks for ensuring a successful portfolio in a dynamic pharmaceutical landscape.

Keywords

Generic portfolio management risk evaluation complex generics strategy

Get full access to this article

View all access options for this article.

References

Generic drugs: revolutionary change in the global pharmaceutical industry. Indxx, www.nasdaq.com/article/generic-drugs-revolutionary-change-in-the-global-pharmaceutical-industry-cm576603#/ixzz4Bf3c1xzJ (2016, accessed 1 July 2016).

Thakur

Ramacha

. Pharmaceutical business strategy: a generics perspective. J Intellectual Property Rights 2012; 17: 484–496.

Kakkar

. Pateny cliff mitigation strategies: giving new life to blockbusters. Expert Opin Ther Pat 2015; 25: 1353–1359.

Sax F, Huml RA and Ng-Cahin J. Clinical aspects of pharmaceutical portfolio management. In: Antonijevic Z (ed.) Optimization of pharmaceutical R&D programs and portfolios: design and investment strategy (Chapter 2). Springer, 2015, pp.19–33.

Stevenson

. Creating real value in pharmaceuticals: driving business development through portfolio strategy. Bus Dev Licensing J 2009; 7: 20–24.

Bhoopathy S, Silchenko S, Wang X and Murray LJ. Strategies for the equivalence assessment of locally acting complex drug products: focus on alternative methodologies. AAPS Newsmagazine, February 2015,pp.13–16.